XML 31 R19.htm IDEA: XBRL DOCUMENT
v3.8.0.1

License and Collaboration Agreements (Tables) | 3 Months Ended
--- | ---
Mar. 31, 2018
Organization Consolidation And Presentation Of Financial Statements [Abstract] |
License, Collaboration and Other Revenue | In accordance with our collaboration agreements, we recognized license, collaboration and other revenue as follows (in thousands):
|  |  |  | Three months ended March 31, |
Partner |  | Drug or Drug Candidate |  | 2018 |  |  | 2017 |
Baxalta Incorporated/Shire |  | ADYNOVATE® |  | $ | 10,011 |  |  | $ | — |
Eli Lilly and Company |  | NKTR-358 |  |  | 2,354 |  |  |  | — |
Amgen, Inc. |  | Neulasta® |  |  | 1,250 |  |  |  | 1,250 |
AstraZeneca AB |  | MOVANTIK® and MOVANTIK® fixed-dose combination program |  |  | — |  |  |  | 3,000 |
Other |  |  |  |  | 112 |  |  |  | 1,842 |
License, collaboration and other revenue |  |  |  | $ | 13,727 |  |  | $ | 6,092 |
Changes in Deferred Revenue Balance from Collaboration Agreements | The following table presents the changes in our deferred revenue balance from our collaboration agreements during the three months ended March 31, 2018:
|  | Three months ended March 31, 2018 |
Deferred revenue—December 31, 2017 |  | $ | 37,970 |
Transition adjustment related to adoption of ASC 606 |  |  | (1,953 | )
Recognition of previously unearned revenue |  |  | (3,678 | )
Deferred revenue—March 31, 2018 |  | $ | 32,339 |

X
- Definition Tabular disclosure of the type of arrangements and the corresponding amounts that comprise the current and noncurrent balance of deferred revenue as of the balance sheet date. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 13.A.4(a).Q1) -URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 8 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6935-107765 + Details
Name: | us-gaap_DeferredRevenueByArrangementDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of contractual arrangements that involve two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity. Additionally, the element may include all other transactions of the entity categorized collectively, if such comparison of collaborative arrangements as a component of all transactions of the entity is desired. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 808 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434 + Details
Name: | us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration